Posted by phidippus on October 28, 2017, at 14:36:10
In reply to thinking of making a change, posted by Melusine on October 28, 2017, at 10:13:40
Its hard to suggest anything when we don't know what you're on or what you've been on.
Buprenorphine, a partial mu opioid agonist commonly used in addiction treatment, may also play a future role in helping patients with treatment-resistant depression. One randomized study of 88 patients found that those who took very low doses of buprenorphine for 2 or 4 weeks had significantly lower scores on the Beck Suicide Ideation Scale, compared with their counterparts on placebo.
Drugs with anti-inflammatory properties may also have a role. One study of 60 patients found that the tumor necrosis factoralpha antagonist infliximab may benefit patients with treatment-resistant depression who have high inflammatory biomarkers at baseline
Riluzole is associated with antidepressant effects in patients with treatment-resistant depression, according to results of an open-label study reported in the January issue of the American Journal of Psychiatry. Riluzole is a glutamate-modulating agent currently approved by the U.S. Food and Drug Administration for the treatment of amyotrophic lateral sclerosis.
Scopalamine is another agent that can be trialed.
Eric
poster:phidippus
thread:1095641
URL: http://www.dr-bob.org/babble/20161215/msgs/1095648.html